Pioneering Cancer Treatment with Dye-Drug Conjugates
Lahjavida, founded by Lyle Small as a spinoff of his industrial dye company Chromatic Technologies, Inc., has discovered and validated a novel drug delivery platform called Dye-Drug Conjugate (DDC). This cutting-edge technology empowers and enhances standard cancer treatments to precisely target metastatic tumors anywhere in the body while protecting healthy tissues. Once the DDC reaches the tumor environment, the conjugate is cleaved, activating the drug to destroy the tumor while preserving healthy cells.

Expertise and Innovation in Dye Technology
Our scientists have spent 25 years inventing dye technology to perform in the most demanding environments. This extensive experience and well-established gold nanoparticle technology place Lahjavida at the forefront of cancer therapeutic development. Our DDC technology uses a unique tumor-targeting dye to deliver chemotherapy drugs specifically to cancer cells, ensuring minimal toxicity to healthy tissue.

The Promise of a Safer, More Effective Therapy
Taken together, our expertise, technology, and strategic partnerships hold the promise and potential to develop a cancer drug therapy that is safer and more effective than many current treatments. The breathtaking potential of our technology is illustrated in Figure 1 (below), which shows different types of cancer cells that selectively bind with a single fluorescing dye. This image suggests a broad impact in targeting various cancers, regardless of type or stage, making Lahjavida's approach a promising candidate for future cancer treatments.

Revolutionary Cancer Treatment Technology: Dye-Drug Conjugates (DDC)

Precision medicine is an improvement, but…

Immunotherapy (IT)

Advantages:

Highly effective in some patients.
Treats otherwise untreatable patients.
Low tumor maintenance.

Disadvantages

$1,000,000 per patient.
Limite scope: 8% of patients potentially eligible.
Side-effects such as a negative immune response.
Genetic modifications of patients T-cells.

Antibody Drug Conjugates (ADCs)

Advantages:

Effective targeting.
Good efficacy.

Disadvantages

Limited applicability.
High complexity.
Large molecule.
Low drug delivery load.
Safety concerns.
Expensive.
Unstable molecule.
Negative and poorly understood side-effects.

Dye-Drug Conjugates (DDCs)

Advantages:

Potential to treat over 30 different cancer types.
Accurate targeting of cancerous cells.
Low systemic toxicity.
High payload delivery.
Small molecule.
Streamlined and consistent manufacturing.
Cost-effective and accessible.

Lahjavida DDC's Specific Mechanism of Action (MOA):

Circulation: DDC (Dye Drug Conjugate) circulates in the bloodstream.
Tumor Cell Targeting: DDCs preferentially bind to tumor cells due to the high concentration of organic anion-transporting polypeptides (OATPs) on these cells. OATPs transport DDCs into the tumor cells.
Mitochondrial Disruption: Inside tumor cells, DDCs accumulate in mitochondria, where they are cleaved to release the drug. This disrupts cellular energy production, leading to cell death.
Lysosomal Release: DDCs also accumulate in lysosomes, where cathepsin B cleavage releases the drug into the tumor cell.
Target Binding and Cell Death: The released drug binds to its targets (DNA and microtubules), resulting in apoptotic cell death.

THE TECHNOLOGY

Proprietary dyes demonstrate impressive cancer cell uptake

Significant “Dye-1” uptake in the cancer cell line with minimum dye uptake in normal cells

DDCs exhibit strong uptake in cancer cells.

Promising Transformative Cancer Treatment with Dye-Drug Conjugates (DDCs)

Our DDCs (Dye-Drug Conjugates) are revolutionizing cancer treatment. Our research shows that DDCs effectively eliminate cancer cells, with nearly 100% tumor cell death within 72 hours of exposure. Plus, we observed a significant slowdown in tumor growth with just two doses administered intravenously (IV) at 10 mg/kg and 15 mg/kg on Day 11. Explore how our innovative approach is making strides in fighting cancer.

Revolutionary Cancer Treatment Technology: Dye-Drug Conjugates (DDC)

Precision medicine is an improvement, but…

Lahjavida DDC's Specific Mechanism of Action (MOA):

​

Circulation: DDC (Dye Drug Conjugate) circulates in the bloodstream.​

Tumor Cell Targeting: DDCs preferentially bind to tumor cells due to the high concentration of organic anion-transporting polypeptides (OATPs) on these cells. OATPs transport DDCs into the tumor cells.​

Mitochondrial Disruption: Inside tumor cells, DDCs accumulate in mitochondria, where they are cleaved to release the drug. This disrupts cellular energy production, leading to cell death.​

Lysosomal Release: DDCs also accumulate in lysosomes, where cathepsin B cleavage releases the drug into the tumor cell.​

Target Binding and Cell Death: The released drug binds to its targets (DNA and microtubules), resulting in apoptotic cell death.

THE TECHNOLOGY

Proprietary dyes demonstrate impressive cancer cell uptake

DDCs exhibit strong uptake in cancer cells.

Promising Transformative Cancer Treatment with Dye-Drug Conjugates (DDCs)

Circulation: DDC (Dye Drug Conjugate) circulates in the bloodstream.

Tumor Cell Targeting: DDCs preferentially bind to tumor cells due to the high concentration of organic anion-transporting polypeptides (OATPs) on these cells. OATPs transport DDCs into the tumor cells.

Mitochondrial Disruption: Inside tumor cells, DDCs accumulate in mitochondria, where they are cleaved to release the drug. This disrupts cellular energy production, leading to cell death.

Lysosomal Release: DDCs also accumulate in lysosomes, where cathepsin B cleavage releases the drug into the tumor cell.